From ASCOT to Asia: A More Active and Successful Approach in Preventing Cardiovascular Disease

Area of Science:

• Cardiology
• Vascular Biology
• Pharmacology

Background:

• Cardiovascular disease (CVD) prevalence is rising globally.
• Hypertension and dyslipidemia are key CVD risk factors, with co-existence reported in 15-31% of cases.
• Combined hypertension and dyslipidemia exacerbate vascular endothelial damage, accelerating atherosclerosis.

Purpose of the Study:

• To review the benefits of combined treatment for hypertension and dyslipidemia in CVD prevention.
• To highlight evidence from major trials and recent Asian studies.
• To emphasize the role of single-pill combinations in improving patient outcomes.

Main Methods:

• Literature review of epidemiological data.
• Analysis of findings from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
• Inclusion of recent clinical studies from Asia focusing on combination therapy.

Main Results:

• Concurrent management of hypertension and dyslipidemia offers synergistic benefits for vascular endothelium.
• Single-pill combination of amlodipine and atorvastatin improves adherence and CVD prevention.
• Aggressive management reduces future cardiovascular events across diverse populations.

Conclusions:

• Combined therapy for hypertension and dyslipidemia is crucial for effective CVD prevention.
• Single-pill formulations enhance treatment adherence and efficacy.
• Targeted management strategies are vital for reducing global CVD burden.